Early infantile developmental and epileptic encephalopathy

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:1934OMIM:617493G40.3
Who is this for?
Show terms as
19Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Early infantile developmental and epileptic encephalopathy (EIDEE), historically known as Ohtahara syndrome or early infantile epileptic encephalopathy with suppression-burst, is a severe neurological disorder characterized by the onset of intractable seizures within the first few months of life. It is one of the most severe forms of epilepsy, typically presenting with tonic spasms that may occur in clusters, along with a characteristic suppression-burst pattern on electroencephalography (EEG). The condition profoundly affects the central nervous system, leading to severe developmental delay or regression, intellectual disability, and progressive neurological deterioration. Many affected infants may transition to other epileptic syndromes such as West syndrome or Lennox-Gastaut syndrome over time. The causes of early infantile developmental and epileptic encephalopathy are heterogeneous. Structural brain malformations (such as hemimegalencephaly, porencephaly, or cortical dysplasia) and genetic mutations are recognized etiologies. Numerous genes have been implicated, including STXBP1, KCNQ2, SCN2A, ARX, CDKL5, and others, reflecting the broad genetic heterogeneity of this condition. Both de novo dominant mutations and autosomal recessive inheritance patterns have been described depending on the specific genetic cause. Treatment remains largely supportive and symptomatic. Antiseizure medications such as phenobarbital, vigabatrin, and others are used but seizures are frequently refractory to medical therapy. In cases with identifiable structural lesions, epilepsy surgery may be considered. Adrenocorticotropic hormone (ACTH) or ketogenic diet may be tried in some patients. Despite treatment, the prognosis is generally poor, with significant morbidity and mortality. Many children experience profound neurodevelopmental impairment, and some may not survive beyond early childhood.

Also known as:

Clinical phenotype terms— hover any for plain English:

Focal motor seizureHP:0011153Epileptic encephalopathyHP:0200134EEG with burst suppressionHP:0010851Focal tonic seizureHP:0011167
Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Early infantile developmental and epileptic encephalopathy.

View clinical trials →

No actively recruiting trials found for Early infantile developmental and epileptic encephalopathy at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Early infantile developmental and epileptic encephalopathy community →

Specialists

19 foundView all specialists →
PA
Pooja Agarwala
Specialist
1 Early infantile developmental and epileptic encephalopathy publication
NK
Nilesh Kurwale
Specialist
1 Early infantile developmental and epileptic encephalopathy publication
SC
Sagnik Chatterjee
Specialist
1 Early infantile developmental and epileptic encephalopathy publication
LY
Li-Fei Yu
Specialist
1 Early infantile developmental and epileptic encephalopathy publication
XZ
Xiao-Mei Zhu
Specialist
1 Early infantile developmental and epileptic encephalopathy publication
TW
Tian-Shuang Wang
Specialist
1 Early infantile developmental and epileptic encephalopathy publication
YZ
Yun-Jian Zhang
Specialist
1 Early infantile developmental and epileptic encephalopathy publication
VJ
Vivek Jain
Specialist
1 Early infantile developmental and epileptic encephalopathy publication
PG
Pradeep Goyal
BRONX, NY
Specialist
1 Early infantile developmental and epileptic encephalopathy publication
AP
Anna Jansen, MD, PhD
Silver Spring, Maryland
Specialist

Rare Disease Specialist

PI on 2 active trials
PS
Praveena L Samson
Specialist
1 Early infantile developmental and epileptic encephalopathy publication
UM
Udita Mahadevia
Specialist
1 Early infantile developmental and epileptic encephalopathy publication
TG
Tamanna Golani
Specialist
1 Early infantile developmental and epileptic encephalopathy publication
RV
Ramprasad Vedam
Specialist
1 Early infantile developmental and epileptic encephalopathy publication
BN
Bhuvandeep Narang
Specialist
1 Early infantile developmental and epileptic encephalopathy publication
SM
Sakthivel Murugan
Specialist
1 Early infantile developmental and epileptic encephalopathy publication
ZM
Zachary Grinspan, MD
Aurora, Colorado
Specialist

Rare Disease Specialist

PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Early infantile developmental and epileptic encephalopathy.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Early infantile developmental and epileptic encephalopathyForum →

No community posts yet. Be the first to share your experience with Early infantile developmental and epileptic encephalopathy.

Start the conversation →

Latest news about Early infantile developmental and epileptic encephalopathy

Disease timeline:

New recruiting trial: A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine

A new clinical trial is recruiting patients for Early infantile developmental and epileptic encephalopathy

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Early infantile developmental and epileptic encephalopathy

What is Early infantile developmental and epileptic encephalopathy?

Early infantile developmental and epileptic encephalopathy (EIDEE), historically known as Ohtahara syndrome or early infantile epileptic encephalopathy with suppression-burst, is a severe neurological disorder characterized by the onset of intractable seizures within the first few months of life. It is one of the most severe forms of epilepsy, typically presenting with tonic spasms that may occur in clusters, along with a characteristic suppression-burst pattern on electroencephalography (EEG). The condition profoundly affects the central nervous system, leading to severe developmental delay o

At what age does Early infantile developmental and epileptic encephalopathy typically begin?

Typical onset of Early infantile developmental and epileptic encephalopathy is neonatal. Age of onset can vary across affected individuals.

Which specialists treat Early infantile developmental and epileptic encephalopathy?

19 specialists and care centers treating Early infantile developmental and epileptic encephalopathy are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.